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Edited by Robert BaroukiAbstract Rainbow trout gill tissue was used to examine the role
of somatostatin (SS) on insulin-like growth factor-I (IGF-I)
receptor expression. In vivo implantation of ﬁsh with somato-
statin-14 (SS-14) reduced expression of IGF-I receptor mRNAs
as well as [125I]-IGF-I binding. In vitro incubation of gill ﬁla-
ments with SS-14 or various SS isoforms, including SS-28 and
[Tyr7, Gly10]-SS-14-containing peptides, directly inhibited IGF-
I receptor mRNA expression. SS-14 also inhibited [125I]-IGF-I
binding in vitro. These data indicate that SSs inhibit the mRNA
and functional expression of IGF-I receptors in gill, and suggest
that SSs regulate growth in an extrapituitary manner by reduc-
ing sensitivity to IGF-I.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Growth in vertebrates is controlled by the growth hormone
(GH)-insulin-like growth factor-I (IGF-I) axis [1–3]. GH re-
leased from the pituitary gland binds to its receptors and stim-
ulates IGF-I synthesis and secretion from liver and other sites,
evoking biological actions through an IGF receptor that is dis-
tinct from the insulin receptor [1,2]. A majority of IGF-I is
produced in the liver under the control of GH; however,
extra-hepatic IGF-I mRNA expression may in some cases be
independent of GH-stimulation, and IGF-I may exert auto-
crine or paracrine eﬀects [3]. For example, paracrine eﬀects
are observed in the gill where IGF-I produced locally has
osmoregulatory eﬀects [4]. Additional studies also suggest that
IGF-I mediates some of the osmoregulatory actions of GH in
marine ﬁsh; however, the eﬀectiveness of IGF-I in increasing
salinity tolerance appears to only last for short time periods
[5].Abbreviations: IGF-I; insulin-like growth factor-I; IGFR-IA, insulin-
like growth factor-I receptor, subtype A; IGFR-IB, insulin-like growth
factor-I receptor, subtype B; GH, growth hormone; PPSS, preproso-
matostatin; SS, somatostatin
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doi:10.1016/j.febslet.2007.08.079Most research on the control of growth has focused on the
regulation of GH production and release from the pituitary
gland. GH is produced and secreted in a manner reﬂective of
the balance of stimulatory and inhibitory controls received
by somatotrophs [6]. Evidence suggests that basic mechanisms
of the synthesis and release of GH have been conserved in ver-
tebrates [7]. Somatostatins (SS) are the primary inhibitors of
GH release [8]. Interestingly, studies of ﬁsh, which possess
numerous forms of SS [9], revealed that SSs are not equipotent
in their GH-inhibiting actions. For example, SS-14, SS-28, and
[Pro2]-SS-14 reduced GH release, while salmonid SS-25, which
contains [Tyr7, Gly10]-SS-14, and catﬁsh SS-22, a unique SS
form, have no eﬀect on GH release [8]. Knowledge of growth
control mechanisms operating outside the level of the pitui-
tary, such as GH receptor regulation and IGF-I receptor
regulation, and the role of SSs in these mechanisms is just
emerging.
IGF-I elicits biological responses through an IGF-I receptor
(IGFR-I) in the plasma membrane of target tissues. The
importance of IGFR-I in regulating development and survival
is demonstrated by the death of IGFR null mice within min-
utes after birth [10]. IGF-I receptors are similar in structure
to the INS receptor with the a2b2 conﬁguration [10]. Two
IGFR-I mRNAs (IGFR-IA and IGFR-IB) encoded by inde-
pendent genes have been identiﬁed in the rainbow trout [11],
but the signiﬁcance of these multiple mRNAs is not clear. Reg-
ulation of IGFR-Is has not been extensively studied. In mam-
mals, fasting increased IGF-I binding and IGFR-I mRNA
expression in lung, stomach, kidney and heart [12]. In rainbow
trout, fasting reduced IGF-I binding as well as IGFR-IA and
IGFR-IB mRNA expression in liver, adipose, and gill; how-
ever, fasting had no eﬀect on expression of IGFR-I in skeletal
muscle and increased expression of IGFR-Is in cardiac muscle
[13]. Biga et al. [14] showed that treatment of rainbow trout
with recombinant bovine GH reduced IGFR-IA expression
in the heart.
Increasing evidence suggests that SSs also play extra-pitui-
tary roles in the regulation of growth. In vivo administration
of SS-14 inhibited organismal growth of rainbow trout in con-
cert with reduced plasma concentrations of GH and IGF-I
[15]. In addition, SS-14 reduced hepatic sensitivity to GH in
rainbow trout by decreasing the transcription of GH receptor
(GHR) mRNAs and by internalizing surface GHRs [16]. A
role of SSs in regulating IGF-I sensitivity was suggested by
the observation that SS-14 inhibited 35SO4 incorporation into
gill cartilage of rainbow trout incubated in vitro [15]. In this
study, rainbow trout were used as a model to clarify the role
of SS in regulating growth and to test the hypothesis that
SSs inhibit IGFR-I expression. Rainbow trout were chosenblished by Elsevier B.V. All rights reserved.
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are well described, and involve isoforms of hormones as well
as their receptors [2,11]. Gill tissue was used because IGFR-
Is are in high abundance in this tissue and are important bio-
logical targets for IGF-I action [2,11].2. Materials and methods
2.1. Experimental animals
Juvenile rainbow trout of both sexes were obtained from Dakota
Trout Ranch near Carrington, ND and transported to North Dakota
State University where they were maintained in 800 l circular tanks
supplied with recirculated (10% replacement volume per day) dechlori-
nated municipal water at 14 C under a 12L:12D photoperiod. Fish
were fed to satiation twice daily with AquaMax Grower (PMI Nutri-
tion International Inc., Brentwood, MO), except 36–48 h before exper-
imental manipulations. Animals were acclimated to laboratory
conditions for at least 4 weeks prior to experiments.2.2. Experimental conditions
For in vivo experiments, ﬁsh were anesthetized in 0.5% (v/v) 2-phen-
oxyethanol, weighed (initial weight was 58.3 ± 1.3 g), individually
tagged, and implanted intraperitoneally with Alzet mini-osmotic
pumps (model 1007D, Alza Corp., Palo Alto, CA) as previously de-
scribed [15]. The mini-pumps contained either 0.75% (w/v) NaCl (con-
trol) or 4 · 104 M somatostatin-14-I (SS-14-I; treated) and had a ﬂow
rate established to be 0.135 ll/h; this would deliver ca. 5.8 · 1011 mol
SS-14-I/h for a period of up to 29 days at 14 C. SS-14-I, obtained
from Sigma, St. Louis, MO (S 9129), has the sequence ﬁrst described
by Brazeau et al. [17], which is highly conserved among vertebrates
and which is derived from the precursor designated preprosomatosta-
tin I (PPSS I) [9]. Once-daily feeding to satiety was recommenced 5
days after implantation and continued for the duration of the experi-
ment, except 24 h prior to terminal sampling when feeding was sus-
pended. After 20 days of implantation, ﬁsh were anesthetized as
before, and the blood was collected into heparinized 2.0-ml tubes
and tissues were removed, placed into 1.5-ml tubes and immediately
frozen on dry ice. Plasma and gills were stored at 80 C for later anal-
yses. Plasma SS-14-I was measured by a speciﬁc radioimmunoassay
[15].
In vitro experiments were conducted on isolated gill ﬁlaments as
adapted from McCormick and Bern [18]. Fish were anesthetized with
0.5% (v/v) 2-phenoxyethanol, bled, and the gill arches were removed
from both sides of the ﬁsh and stored in ice-cold Dulbecco’s Modiﬁed
Eagle’s Medium Base (DMEM) (Sigma D-5030 plus in mM: 27 NaCl,
4 L-glutamine, 4 glucose, 10 HEPES, 4 NaHCO3, 0.24% BSA; pH 7.6).
In a petri dish on ice, individual gill ﬁlaments were dissected from the
arches, pooled, and then washed three times with DMEM. Nine to ele-
ven gill ﬁlaments were placed in each well of a 24-well culture plate.
One-half milliliter DMEM was added to each well and the ﬁlaments
were allowed to recover for 1 h at 14 C with gyratory shaking
(100 rpm) under 100% oxygen. After recovery, medium was removed
and the ﬁlaments were rinsed with 0.5 ml DMEM before addition of
700 ll DMEM plus antibiotics (100 U/ml penicillin; 100 lg/ml strepto-
mycin; 0.1% (v/v) fungizone, pH 7.6) to each well. Filaments were incu-
bated in medium alone (control) or in medium containing various
concentrations of SS for up to 24 h. The concentration of hormones
used and the length of incubation for each experiment is indicated in
each ﬁgure legend. The isoforms of SS tested included the PPSS I-de-
rived peptides, SS-14-I and SS-28-I (Sigma S 6135), and the PPSS II-
derived peptides, SS-14-II, SS-25-II and SS-28-II, which contain
[Tyr7, Gly10]-SS-14 at their C-terminus (custom synthesized by Dr.
D. Smith, Creighton University, Omaha, NE). Incubations were
stopped by removal of the incubation medium and freezing the tissue
immediately on dry ice for later analyses of IGF-I binding and IGFR-I
mRNA expression. Experiments were repeated 2–3 times.2.3. IGF-I binding
Labeling of trout IGF-I (tIGF-I; GroPep, LTD, Adelaide, Austra-
lia) with 125I (as [125I]-NaI,1 mCi; ICN Biomedicals, Irvine, CA,
USA) and binding of 125I-labeled tIGF-I to microsomes prepared fromgill ﬁlaments was performed according to Parrizas et al. [19]. Protein
was determined by the BioRad Inc. (Hercules, CA) dye-binding meth-
od for microplates using bovine serum albumin as standard.
2.4. RNA extraction and analysis
Gill ﬁlaments were homogenized and total RNA was extracted using
500 ml of TRI Reagent (Molecular Research Center, Cincinnati, OH)
as speciﬁed by the manufacturer’s protocol. Each RNA pellet was
redissolved in 75 ll RNase-free deionized water and quantiﬁed by
ultraviolet (UV A260) spectrophotometry. RNA samples were then
stored at 80 C until further analysis.
RNA was reverse transcribed in 10 ll reactions using 200 ng total
RNA (2 ll) and 8 ll TaqMan reverse transcription reagents (which
included 5.5 mMMgCl2, 500 lM each dNTP, 2.5 lM oligo d(T)16 pri-
mer, 0.4 U/ ll RNase inhibitor, and 3.125 U/ml MultiScribe reverse
transcriptase) according to the manufacturer’s protocol (Applied Bio-
systems, Foster City, CA). Reactions without reverse transcriptase
were included as negative controls to exclude the possibility of contam-
ination with genomic DNA; no ampliﬁcation was detected in negative
controls.
Steady-state levels of IGFR-IA and IGFR-IB mRNA were deter-
mined by quantitative real-time PCR as described previously [19].
Brieﬂy, real-time reactions were carried out for samples, standards,
and no-template controls in a 10 ll volume, containing 1 ll cDNA
from the reverse transcription reactions, 5 ll TaqMan Universal
PCR Master Mix, and 1 ll of each forward primer, reverse primer,
and probe at concentrations optimized for each RNA species. Cycling
parameters were set as follows: 95 C for 10 min and 45 cycles of 95 C
for 15 s and 60 C for 1 min. Cross reaction was assessed by substitut-
ing alternate primer/probe sets in TaqMan assays for each standard;
no ampliﬁcation was observed under these conditions. Sample copy
number was calculated from the threshold cycle number (CT) and
relating CT to a gene-speciﬁc standard curve, followed by normalized
to b-actin (GenBank Accession No. AF157514) [20,21].
2.5. Data analysis
Data are expressed as means ± S.E.M. Statistical diﬀerences were
estimated by Student’s t-test or ANOVA followed by Duncan’s test,
as appropriate, using SigmaStat (SPSS, Chicago, IL). A probability
level of 0.05 was used to indicate signiﬁcance. Ligand binding charac-
teristics (aﬃnity, Kd, and capacity, Bmax) were calculated with the
SigmaPlot Ligand Binding Module (SPSS). For ease of comparison,
mRNA expression data are illustrated as % of control. In all cases, sta-
tistics were performed on untransformed data.3. Results
3.1. In vivo eﬀects of somatostatin
Implantation of rainbow trout signiﬁcantly elevated plasma
SS-14-I levels (7.4 ± 0.2 ng/ml) over those observed in saline-
implanted ﬁsh (5.3 ± 0.3 ng/ml). Two isoforms of IGFR
mRNA were detected: IGFR-IA and IGFR-IB. SS-14-I
implantation reduced steady-state levels of IGFR-IA mRNA
by 36% and of IGFR-IB by 45.4% compared to those observed
in saline-implanted controls (Fig. 1A). SS-14-I implantation
also reduced functional expression of IGFRs as indicated by
125I-tIGF-I binding. Capacity of 125I-tIGF-I binding to gill ﬁl-
ament membranes was reduced 35% in SS-14-I-implanted ﬁsh
compared to controls (Fig. 1B); there were no treatment eﬀects
on binding aﬃnity (data not presented).
3.2. In vitro eﬀects of somatostatin
SS-14-I directly inhibited the expression of IGFR-I mRNAs
in gill ﬁlaments incubated in vitro. Steady-state levels of both
IGFR-IA and IGFR-IA mRNAs were inhibited in a dose-
dependent manner, with signiﬁcant inhibitory eﬀects on
IGFR-IB beginning at 1 ng/ml (Fig. 2A); the ED50 for inhibi-
tion of both IGFR-IA and IGFR-IB mRNAs was estimated to
AB
Fig. 1. Eﬀects of SS-14-I implantation into rainbow trout for 20 days
on steady-state levels of IGFR-IA and IGFR-IB mRNAs in gill
ﬁlaments (A) and binding of 125I-trout IGF-I to membranes prepared
from gill ﬁlaments (B). Data are presented as means ± S.E.M. (n = 8); *
indicates signiﬁcantly (P < 0.05) diﬀerent from control. SS-14-I,
somatostatin-14-I; IGFR-IA, insulin-like growth factor-I receptor
subtype A; IGFR-IB, insulin-like growth factor-I receptor subtype B;




Fig. 2. Eﬀects of SS-14-I (A, B) and of other somatostatin isoforms
(C) on steady-state levels of IGFR-IA and IGFR-IB mRNAs in gill
ﬁlaments of rainbow trout incubated in vitro. Tissues were incubated
with the concentration of SS-14-I indicated for 6 h (A), with 100 ng/ml
SS-14-I for the time indicated (B), or with 100 ng/ml of the SS isoform
indicated for 6 h (C). Data are presented as means ± S.E.M. (n = 8);
groups with diﬀerent letters are signiﬁcantly (p < 0.05) diﬀerent from
each other for a given IGFR-I mRNA type. SS-14-I, somatostatin-14-
I; IGFR-IA, insulin-like growth factor-I receptor subtype A; IGFR-
IB, insulin-like growth factor-I receptor subtype B.
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served at 1000 ng/ml.
The time course for SS-14-I action on steady-state levels of
IGFR-IA and IGFR-IB mRNAs is shown in Fig. 2B. An
abrupt decrease in the expression of IGFR-I mRNAs was ob-
served after 3 h of treatment with SS-14-I. Maximum inhibi-
tion of IGFR-IA and IGFR-IB mRNA levels was observed
after 6 h. There after, levels increased slightly or remained con-
stant for the duration of the 24-h experiment.
The inﬂuence of various SS isoforms on the expression of
IGFR-Is is shown in Fig. 2C. The N-terminally extended form
of SS-14-I, SS-28-I, as well as the N-terminally extended [Tyr7,
Gly10]-substituted forms of SS, SS-25-II and SS-28-II, inhib-
ited expression of both IGFR-IA and IGFR-IB mRNAs com-
pared to controls. However, the 14-amino acid [Tyr7, Gly10]-
substituted form of SS, SS-14-II, did not aﬀect the expression
of IGFR-IA, but had a slight yet signiﬁcant eﬀect on the
expression of IGFR-IB.
SS-14-I also had a direct eﬀect on the functional expression
IGF-I receptors. Binding capacity of 125I-tIGF-I to micro-
somes prepared from gill ﬁlaments incubated in vitro was re-
duced 66% with SS-14-I treatment compared to controls
(Fig. 3). Similar to in vivo ﬁndings, SS-14-I had no eﬀects on
the aﬃnity of IGF receptors (data not presented).4. Discussion
This study conﬁrms our starting hypothesis and indicates
that SSs inhibit the expression of IGFR-Is in the gill tissue
of a teleost ﬁsh. These ﬁndings, the ﬁrst reporting the eﬀects
of SSs on IGF-I sensitivity to our knowledge, contribute to a
broader understanding of the role of SSs in regulating the
growth of vertebrates.
The role of SSs in regulating IGFR-I expression is supported
by several observations. First, in vivo experiments conﬁrm that
Fig. 3. Eﬀects of SS-14-I on binding of 125I-trout IGF-I to membranes
prepared from gill ﬁlaments of rainbow trout incubated in vitro. Gill
ﬁlaments were incubated in the presence of 100 ng/ml SS-14-I for 6 h.
Data are presented as means ± S.E.M. (n = 8); * indicates signiﬁcantly
(P < 0.05) diﬀerent from control. SS-14-I, somatostatin-14-I; IGF-I,
insulin-like growth factor-I.
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physiologically relevant response, occurring in the range of
SSs concentrations measured in the plasma of ﬁsh [22]. Second,
the eﬀects of SSs on the expression of IGFR-I are direct and
rapid, occurring in <3 h. Third, SSs not only aﬀects steady-
state levels of IGFR-I mRNAs, but also reduces 125I-tIGF-I
binding capacity. Taken together, the current ﬁndings indicate
that SS inhibits the biosynthesis and functional expression of
IGF-I receptors to reduce target organ sensitivity to IGF-I.
The current ﬁndings also provide additional information
about SS structure–function relationships. Many species pos-
sess SSs in addition to SS-14-I, the ﬁrst characterized form that
is highly conserved among vertebrates [9,17]. The molecular
heterogeneity of the SS family of peptides arises from tissue-
speciﬁc diﬀerential processing of the precursor protein that
contains SS-14-I at its C-terminus (preprosomatostatin I.
PPSS I), and from the existence of multiple SS genes that en-
code distinct PPSSs [9]. Teleost ﬁsh for example express PPSS
I and PPSS II, which contains [Tyr7, Gly10]-SS-14 (SS-14-II) at
its C-terminus [9]. Several studies have indicated diﬀerences in
biological activity among SS isoforms and that these diﬀer-
ences result from interactions with the SS receptors [23,24].
Notably, SS-14-I, SS-28-I, and [Pro2]-SS-14 (SS-14-III) inhib-
ited GH release, while [Tyr7, Gly10]-SS-14- (SS-14-II) contain-
ing salmonid SS-25 and catﬁsh SS-22, an unique SS form, do
not [8]. The current ﬁndings indicate that all SS forms inhibit
IGFR-I expression, except SS-14-II, which did not aﬀect
IGFR IA mRNA levels. This diﬀerence in eﬃcacy cannot be
attributed to the presence of Tyr7, Gly10 substitutions, because
SS-28-II and SS-25-II, which both possess [Tyr7, Gly10]-SS-14
(SS-14-II) at their C-terminus, strongly inhibited the expres-
sion of IGFR-Is; therefore, other structural features or combi-
nation of features are likely important for receptor selectivity
in mediating SS action in gill tissue. It is interesting to note,
however, that for a given SS form, IGFR-IA and IGFR-IB
mRNA levels responded in a like manner. Similar ﬁndings
were observed with SS on the two forms of GH receptor in
trout liver [16].
The observed actions of SSs on IGFR-I expression extend
our knowledge of factors regulating target organ sensitivity
of IGF-I. In mammals and ﬁsh, fasting results in the downregulation of IGF-I receptors and decreased expression of
IGFR-I mRNAs in numerous tissues [12,13,25]. Decreased
sensitivity to IGF-I would be adaptive during nutritional
restriction by suppressing growth and shifting the allocation
of energy to maintenance of critical processes. The role of
SS in fasting-associated growth suppression was suggested
by elevated plasma levels of SS observed in mammals and ﬁsh
during fasting [22] and are conﬁrmed by the current ﬁndings.
The possibility remains, however, that some of the observed
eﬀects were due to feedbacks resulting from locally produced
IGF-I. A previous study in trout has shown that IGF-I can
down-regulate the number of IGFR-I on the surface of cardio-
myocytes [26].
The mechanisms by which SSs modulate IGFR-I expression
are not known. SSs are known to interact with numerous SS
receptor (SSTR) subtypes; ﬁve subtypes have been character-
ized in mammals (SSTR 1-5) and four have been characterized
in ﬁsh, some with multiple isoforms (SSTR 1A/1B, 2A/2B, 3A/
3B/3C, 5A/5B) [9,27,28]. SS receptors are G-protein coupled
and have been shown to link with numerous cellular eﬀector
pathways, including adenylyl cyclase/cAMP, phospholipase
C/IP3, various ion channels, and MAPK [24]. Recently, SSs
were found to inhibit GHR and IGF-I expression by activating
the MAPK signaling pathway [29]. Activation of the MAPK
pathway was linked to trout SS receptor subtypes 1A, 1B,
and 2 stably expressed in CHO cells (Gong and Sheridan,
unpublished observation).
The present ﬁndings extend our understanding of the role of
SSs in regulating the growth of vertebrates. In addition to
inhibiting organismal growth by suppressing the release of
GH from the pituitary [8,24], SSs appear to have a number
of local, extra-pituitary actions. SSs reduce target organ sensi-
tivity to GH by down regulating GH receptors and decreasing
GHR biosynthesis [16]. Such decreased GH sensitivity would
result in reduced IGF-I production and release, consequences
that explain the depressed IGF-I levels observed in reduced-
growth states (e.g., fasting) [2]. The current observations indi-
cate that SSs also reduce target organ sensitivity to IGF-I by
down regulating IGF-I receptors and reducing IGFR-I biosyn-
thesis. Such comprehensive growth suppressing actions of SSs
are consistent with their lipid and carbohydrate catabolic
actions [22], and suggest that SSs play a pivotal role in energy
allocation by coordinating metabolism with growth and other
processes such as reproduction [8,28,30]. The actions of SSs on
IGFRs also may impact osmoregulation in ﬁsh because of the
role of IGF-I on Na+-K+-ATPase [5]. This notion is supported
by the recent observation that SS-14-I reduced seawater adapt-
ability of rainbow trout [20].
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